MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.18 +0.04 (+0.15%)
Official Closing Price Updated: 7:00 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Thriving in the Age of Overwhelm ↗
Why do so many people feel overwhelmed right now? And what can investors do about it? 
Via The Motley Fool
News headline image
Why Wall Street Is Dead Wrong About This Popular Stock ↗
Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term. 
Via The Motley Fool
Topics Intellectual Property
News headline image
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
News headline image
Addiction Treatment Market Size, Demand, Growth By 2035 ↗
The most recent research report on the "Addiction Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts 
Via Talk Markets
Topics Economy
News headline image
Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies ↗
Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally. 
Via Benzinga
News headline image
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
From Pfizer Inc.
Via Business Wire
News headline image
Rituxan (rituximab) Drug Market Size, Share, Industry Growth By 2035 ↗
The most recent research report on the "Rituxan (rituximab) Drug Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore 
Via Talk Markets
Topics Economy
News headline image
Drugs for Oral Mucositis Market Size, Report Growth By 2035 ↗
The most recent research report on the "Drugs for Oral Mucositis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore 
Via Talk Markets
Topics Economy
News headline image
1 Stock Under $50 with Solid Fundamentals and 2 We Ignore
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
Topics Energy
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
D-Wave Quantum vs. IonQ: Which Quantum Computing Stock Is a Better Buy in 2026? ↗
Explore how two quantum innovators stack up on customer reach, financial health, and risk as they race for commercial leadership in a fast-evolving sector. 
Via The Motley Fool
News headline image
3 Dividend Stocks Yielding Above 5% to Scoop Up Now
These three dividend stocks combine strong yields with resilient businesses. 
Via Barchart.com
Topics Artificial Intelligence
News headline image
3 Blue Chip Dividend Stocks to Buy in June as the Dow Jones Industrial Average Turns 130 ↗
The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe? ↗
The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38% ↗
As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials. 
Via The Motley Fool
News headline image
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know. ↗
The pharma giant is taking steps to expand its portfolio. 
Via The Motley Fool
News headline image
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
What's the Better Dividend Stock Today: AbbVie or Pfizer? ↗
These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Is Relay Therapeutics a Buy After Promising Trial Results? ↗
Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy. 
Via The Motley Fool
News headline image
The Most Important Healthcare Stock You're Not Watching ↗
Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pediatrics Medicine Market Size, Industry Report By 2035 ↗
The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts 
Via Talk Markets
Topics Economy
News headline image
Prediction: Alphabet Will Join the $5 Trillion Club and the Dow Jones Industrial Average in June ↗
Honeywell is spinning off its aerospace segment, which could trigger a shake-up in the Dow Jones Industrial Average this summer. 
Via The Motley Fool
Topics Stocks
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
2 Reasons to Watch PFE and 1 to Stay Cautious
Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell shor... 
Via StockStory
Topics Supply Chain
News headline image
The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗
The market appears to be short-sighted. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
Topics Energy
News headline image
Pfizer Expands Pneumococcal Vaccine Push With New Programs ↗
Pfizer reports Phase 2 infant vaccine data showing a stronger immune response against serotype 3 versus Prevnar 20. 
Via Benzinga
News headline image
How S&P Drug Titan Pfizer Plans To Outdo Its Own $6 Billion Franchise ↗
The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study. 
Via Investor's Business Daily
Topics Stocks
News headline image
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
From Pfizer Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story